$TXTM Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, "In addition to working with CIDP on defining our human clinical trial for Type 2 diabetes, we have been collaborating with a team of leading diabetes researchers based in the US to standardize an investigation model to confirm Phytofare® catechin complex as a primary prevention strategy for autoimmune diabetes and as a glucose regulator for Type 2 diabetes. We want to focus our research on establishing an effective therapeutic dosage point for Phytofare® catechin complex as a first line protocol for diabetes so that we can enter the market on an accelerated basis. The challenge in creating a catechin-based therapy is being able to deliver enough catechins to the system, improve metabolic uptake, and increase residency. We believe Phytofare® can do just that. If we can deliver an all-natural, non-toxic product that eliminates the reliance on insulin injections for many diabetics, this could be a life-changing therapy."

https://finance.yahoo.com/news/protext-pharma...58561.html